These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

275 related items for PubMed ID: 27896507

  • 1. Levonorgestrel-Releasing Intrauterine Systems Versus Oral Cyclic Medroxyprogesterone Acetate in Endometrial Hyperplasia Therapy: A Meta-Analysis.
    Yuk JS, Song JY, Lee JH, Park WI, Ahn HS, Kim HJ.
    Ann Surg Oncol; 2017 May; 24(5):1322-1329. PubMed ID: 27896507
    [Abstract] [Full Text] [Related]

  • 2. Oral and intrauterine progestogens for atypical endometrial hyperplasia.
    Luo L, Luo B, Zheng Y, Zhang H, Li J, Sidell N.
    Cochrane Database Syst Rev; 2018 Dec 04; 12(12):CD009458. PubMed ID: 30521671
    [Abstract] [Full Text] [Related]

  • 3. Relapse risk of endometrial hyperplasia after treatment with the levonorgestrel-impregnated intrauterine system or oral progestogens.
    Ørbo A, Arnes M, Vereide AB, Straume B.
    BJOG; 2016 Aug 04; 123(9):1512-9. PubMed ID: 26630538
    [Abstract] [Full Text] [Related]

  • 4. Levonorgestrel-releasing intrauterine system for endometrial hyperplasia.
    Mittermeier T, Farrant C, Wise MR.
    Cochrane Database Syst Rev; 2020 Sep 06; 9(9):CD012658. PubMed ID: 32909630
    [Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7. Levonorgestrel intrauterine system for endometrial protection in women with breast cancer on adjuvant tamoxifen.
    Chin J, Konje JC, Hickey M.
    Cochrane Database Syst Rev; 2009 Oct 07; (4):CD007245. PubMed ID: 19821400
    [Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9. Levonorgestrel intrauterine system for endometrial protection in women with breast cancer on adjuvant tamoxifen.
    Romero SA, Young K, Hickey M, Su HI.
    Cochrane Database Syst Rev; 2020 Dec 21; 12(12):CD007245. PubMed ID: 33348436
    [Abstract] [Full Text] [Related]

  • 10. Levonorgestrel intrauterine system for endometrial protection in women with breast cancer on adjuvant tamoxifen.
    Dominick S, Hickey M, Chin J, Su HI.
    Cochrane Database Syst Rev; 2015 Dec 09; 2015(12):CD007245. PubMed ID: 26649916
    [Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15. LNG-IUS versus oral progestogen treatment for endometrial hyperplasia: a long-term comparative cohort study.
    Gallos ID, Krishan P, Shehmar M, Ganesan R, Gupta JK.
    Hum Reprod; 2013 Nov 09; 28(11):2966-71. PubMed ID: 23975691
    [Abstract] [Full Text] [Related]

  • 16. Oral Progestogens Versus Levonorgestrel-Releasing Intrauterine System for Treatment of Endometrial Intraepithelial Neoplasia<sup/>.
    Marnach ML, Butler KA, Henry MR, Hutz CE, Langstraat CL, Lohse CM, Casey PM.
    J Womens Health (Larchmt); 2017 Apr 09; 26(4):368-373. PubMed ID: 27901412
    [Abstract] [Full Text] [Related]

  • 17. Levonorgestrel-releasing intrauterine system for atypical endometrial hyperplasia.
    Luo L, Luo B, Zheng Y, Zhang H, Li J, Sidell N.
    Cochrane Database Syst Rev; 2013 Jun 05; (6):CD009458. PubMed ID: 23737032
    [Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 14.